TB Alliance Applauds WHO Prequalification of Macleods Pretomanid Product
NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received prequalification from the World Health
NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received prequalification from the World Health
MANILA (September 3, 2024) – A delegation of experts from Brazil’s National TB Program visited Manila recently to collaborate with
MANILA (25 March 2024)—TB Alliance’s new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding
Indonesia, Kyrgyzstan, Philippines, Ukraine, Uzbekistan, and Vietnam presented results of LIFT-TB operational research program at the Union Conference on Lung
NEW YORK (November 13, 2023)—Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and
ISLAMABAD and PRETORIA (9 November 2023)—The Association for Social Development (ASD) has registered 206 participants with drug-resistant tuberculosis (DR-TB) in
NEW YORK (September 15, 2023) — Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license
“The addition of pretomanid to the Essential Medicines List (EML) of the World Health Organization (WHO) is a critical step